1. The Amgen or AstraZeneca of early-stage cancer drug development.

2. A startup Bristol Myers Squibb or Merck focused on pioneering new cancer therapies.

3. An Eli Lilly or Pfizer that's just starting to build its cancer drug pipeline.

```html

• ELVN-001: A small molecule inhibitor undergoing Phase 1 clinical trials for chronic myeloid leukemia.
• ELVN-002: A small molecule inhibitor in Phase 1 clinical trials for cancers with an abnormal HER2 gene.

```

Enliven Therapeutics, Inc. (ELVN) is a clinical-stage biopharmaceutical company. As described, the company is focused on the discovery and development of small molecule inhibitors for cancer, with its lead candidates, ELVN-001 and ELVN-002, currently in Phase 1 clinical trials.

At this stage of development, Enliven Therapeutics does not have commercial products approved for sale. Therefore, the company does not have major customers that purchase its products. Its operations are funded primarily through investments and, potentially, through research collaborations or grants, rather than product sales to other companies or individuals.

null

Rick Fair, Chief Executive Officer and Member of the Board of Directors Rick Fair has over 25 years of experience in product development and commercialization, with 20 years spent at large pharmaceutical companies. He most recently served as President and Chief Executive Officer of Bellicum Pharmaceuticals, a clinical-stage biopharmaceutical company. Prior to Bellicum, he spent more than 10 years at Roche/Genentech, where he led the Global Product Strategy Oncology/Hematology group, responsible for a $23 billion portfolio and overseeing the launch of five new therapies across solid and hematologic tumors. He also held leadership positions in market access and marketing at Johnson & Johnson. Benjamin Hohl, Chief Financial Officer and Head of Corporate Development Benjamin Hohl joined Enliven Therapeutics from the Healthcare Investment Banking Group at Goldman Sachs & Co LLC, where he worked as an investment banker for nearly a decade (July 2012 to July 2021). In this role, he advised biopharmaceutical and life sciences management teams and boards, executing a broad range of strategic and financing transactions, including over 50 deals totaling more than $75 billion in M&A, equity, and debt financings. He had previously served as Chief Financial Officer of Former Enliven since August 2021 before the company's merger in February 2023. Sam Kintz, Co-founder and Head of Pipeline Sam Kintz is a co-founder of Enliven Therapeutics and previously served as its Chief Executive Officer. Prior to co-founding Enliven, he was an Executive Director of Research at AbbVie and Head of Research at AbbVie Stemcentrx. He also held the position of Vice President, Business Development and Applications, at Biodesy, a biotech startup. His experience includes working at Roche Venture Fund, where he identified and evaluated investment opportunities in the life sciences industry, and as a medicinal chemist at Genentech. Enliven Therapeutics was initially backed by seed capital from OrbiMed and 5AM Ventures, and later secured Series A financing that included Roche Venture Fund, indicating a pattern of involvement with companies supported by private equity and venture capital firms. Joseph P. Lyssikatos, Co-founder and Chief Scientific Officer Joseph P. Lyssikatos is a co-founder of Enliven Therapeutics and serves as its Chief Scientific Officer. Before co-founding Enliven, he was the Vice President of Medicinal Chemistry and DMPK at Biogen. His career also includes roles as an Executive Director at AbbVie, Staff Scientist at Genentech, and Senior Director at Array Biopharma, starting his pharmaceutical career as a medicinal chemist at Pfizer Groton. He has contributed to over 30 programs, leading to the discovery of more than 15 clinical candidates, including four FDA-approved cancer therapies: Koselugo (selumetinib), Mektovi (binimetinib), Tukysa (tucatinib), and Retevmo (selpercatinib). Anish Patel, Co-founder and Chief Operating Officer Anish Patel is a co-founder and the Chief Operating Officer of Enliven Therapeutics.

The key risks to Enliven Therapeutics (ELVN) primarily stem from its nature as a clinical-stage biopharmaceutical company focused on drug development.

1. Clinical Trial and Regulatory Risk: As a clinical-stage company, Enliven Therapeutics' success is highly dependent on its drug candidates, particularly ELVN-001 and ELVN-002, successfully progressing through clinical trials and ultimately receiving regulatory approval. The company is "heavily dependent on its lead candidate ELVN-001 for BCR-ABL, with significant clinical trial risks and regulatory uncertainties." There is a considerable "risk of failing to demonstrate safety and efficacy of product candidates", and even if trials are successful, there is "regulatory uncertainty" regarding obtaining approvals. This risk is inherent in the biopharmaceutical industry, where drug candidates often fail in various stages of development.
2. Financial Sustainability and Need for Additional Funding: Enliven Therapeutics has consistently operated at a loss, with a significant accumulated deficit, reflecting the substantial investments required for pharmaceutical development. "ELVN's financial position reflects substantial investment in R&D, with a need for additional funding to sustain operations." The company's "financial health is a concern, as evidenced by its significant net losses and negative cash flows." To continue advancing its product candidates through clinical trials and toward commercialization, Enliven Therapeutics will likely need to secure additional capital, which could dilute existing shareholders.
3. Competition: The pharmaceutical industry is highly competitive, with numerous established companies and emerging biotech firms vying for market share. Enliven Therapeutics "faces competition from companies with greater financial resources and market presence." Competitors could develop more effective or affordable therapies, achieve regulatory approvals more quickly, or establish strong market positions before Enliven Therapeutics can commercialize its own products.

null

Enliven Therapeutics' main products, ELVN-001 and ELVN-002, target specific cancer markets with the following addressable market sizes:

• ELVN-001 (Chronic Myeloid Leukemia): The global chronic myeloid leukemia (CML) treatment market was valued at approximately USD 8.59 billion in 2023 and is projected to reach USD 16.33 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.4%. Another estimate for the global CML treatment market indicates a value of USD 8.6 billion in 2023, with a projection to reach USD 14.3 billion by 2033, growing at a CAGR of 5.2%. For the 7 major markets (7MM), which include the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan, the CML market reached USD 5.7 billion in 2024 and is expected to grow to USD 8.9 billion by 2035.

• ELVN-002 (Cancers harboring an abnormal HER2 gene): This product targets HER2+ and HER2 mutant tumors, including HER2-positive breast cancer and HER2+ gastric cancer.

  • For the global HER2-positive breast cancer treatment market, it was valued at USD 10.95 billion in 2025 and is projected to reach USD 13.79 billion by 2031, with a CAGR of 3.92%. The 7 major markets (7MM) for metastatic HER2-Positive breast cancer were valued at USD 2,711.6 million in 2024 and are anticipated to reach USD 3,108.1 million by 2035.
  • For HER2+ gastric cancer (including GEJ) in the 7 major markets (7MM), the total market size was approximately USD 700 million in 2024 and is projected to increase through 2034.

Enliven Therapeutics (ELVN), a clinical-stage biopharmaceutical company, is focused on the discovery and development of small molecule inhibitors for cancer. Given its current stage of development, expected revenue growth over the next 2-3 years will primarily be driven by key pipeline advancements and strategic activities rather than product sales.

Here are 3-5 expected drivers of Enliven Therapeutics' future revenue growth:

1. Advancement of ELVN-001 through pivotal clinical trials: A significant driver for future revenue growth is the successful progression and initiation of the Phase 3 ENABLE-2 pivotal trial for ELVN-001 in chronic myeloid leukemia (CML), which is planned for the second half of 2026. Positive initial Phase 1b data for ELVN-001 has already been reported, and continued successful clinical development will be critical to its potential commercialization.
2. Positive clinical data readouts for ELVN-001: Ongoing positive data readouts from the ENABLE trial for ELVN-001 throughout 2026, especially as it advances into later-stage studies, will bolster its market potential and attract further investment or partnerships.
3. Strategic partnerships and licensing agreements: As a clinical-stage company, Enliven Therapeutics may generate future revenue through strategic collaborations, licensing agreements, and partnerships. These could include upfront payments, development milestone payments, and future royalties from ELVN-001 or other pipeline candidates. The company is actively evaluating strategic collaborations to accelerate development timelines or maximize commercial value.
4. Potential for expedited regulatory pathways and market entry for ELVN-001: ELVN-001 has received Orphan Drug Designation for CML, and the company intends to engage with regulatory authorities to discuss potential expedited approval pathways. A faster path to market, should the clinical data support it and regulators agree, would accelerate the timeline for commercialization and subsequent revenue generation.

Share Issuance

• Enliven Therapeutics completed a $200 million equity raise in June 2025, which included the sale of new shares and warrants.
• A stock sale in 2025 grossed approximately $230 million in proceeds, contributing to the company's cash reserves.
• The weighted-average shares outstanding, basic and diluted, increased from 49.858 million in the fourth quarter of 2024 to 62.213 million in the fourth quarter of 2025.

Inbound Investments

• Enliven Therapeutics closed a $200 million equity raise in June 2025.
• In August 2024, the company received a $10 million milestone payment from Cardurion as per an asset purchase agreement established prior to the merger between Imara Inc. and Enliven Inc.

Capital Expenditures

• While specific capital expenditure figures for property, plant, and equipment are not detailed, the company's significant investment is in research and development.
• Research and development expenses for the full year 2025 totaled $85.9 million, an increase from $80.8 million in 2024 and $64.6 million in 2023.
• These expenses are primarily focused on advancing its pipeline of small molecule kinase inhibitors, including ELVN-001 for chronic myeloid leukemia and ELVN-002 for cancers with an abnormal HER2 gene.